We use cookies to ensure that we give you the best experience on our website Learn more

Jun 22, 2018

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

07 / THE ASSOCIATION BETWEEN HYPOMAGNESEMIA AND SURVIVAL IN PATIENTS WITH OVARIAN CANCER

;

Liu, W.;

Qdaisat, A.;

Lopez, G.;

Lorenzo Cohen, L.C.;

Bruera, E.;

Yeung, S.C.

hypomagnesemia

ovarian cancer

survival

cardiovascular condition

Abstract

Abstract

thumbnail

Keywords

hypomagnesemia

ovarian cancer

survival

cardiovascular condition

Abstract

The Association between Hypomagnesemia and Survival in Patients with Ovarian Cancer W. Liu1, A. Qdaisat2, G. Lopez1, L.C. Lorenzo Cohen1, E. Bruera1, S.C. Yeung2. 1MD Anderson Cancer Center, Palliative- Rehabilitation & Integrative Medicine, Houston, USA. 2MD Anderson Cancer Center, Department of Emergency Medicine, Houston, USA. Introduction: Hypomagnesemia is strongly associated with rapid disease progression and increased complications in patients with diabetes. Though it is a known side effect of several antineoplastic agents, its impact on cancer patient outcomes is not frequently studied. Objectives We aimed to examine magnesium abnormalities and survival in ovarian cancer patients who have received platinum-based chemotherapy. Methods We included ovarian cancer patients presenting to MD Anderson Cancer Center (MDACC):1) between 1/1/2004 and 12/31/2014; 2) age 18 years or older; 3) first treatment (surgery or chemotherapy) at MDACC within 60 days of diagnosis; 4) chemotherapy containing cisplatin or carboplatin; and 5) interval between treatments < 3 months. The final cohort consisted of 303 patients. Vital signs and laboratory tests were recorded for baseline (30 days before and on the first treatment day) and treatment course (after first treatment day to 30 days after the last treatment). The association between clinical parameters and survival were analyzed. Results Mean patient age was 62 years. Higher baseline heart rate (OR=1.03, P<0.001) and the prevalence of hypomagnesemia during treatment course (HR=1.10, P<0.001) were significantly associated with shorter survival independent of age, cancer stage, hyponatremia, hypokalemia, and chemotherapy cycles. Intravenous magnesium sulfate replacement (g) (HR=0.96, P=0.002) was associated with longer survival. Conclusions Cardiovascular deconditioning prior to treatment and prevalence of hypomagnesemia are prognostic of survival for ovarian cancer patients receiving platinum-based chemotherapy and surgery. Optimizing cardiovascular condition should be an integral part of the overall treatment preparation. Future research is needed for strategies to detect and prevent hypomagnesemia in this patient population.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.